WO2006008008A3 - Agents diagnostiques et therapeutiques pour pathologies associees au facteur nucleaire d'hepatocyte 4, alpha (hnf4a) - Google Patents
Agents diagnostiques et therapeutiques pour pathologies associees au facteur nucleaire d'hepatocyte 4, alpha (hnf4a) Download PDFInfo
- Publication number
- WO2006008008A3 WO2006008008A3 PCT/EP2005/007457 EP2005007457W WO2006008008A3 WO 2006008008 A3 WO2006008008 A3 WO 2006008008A3 EP 2005007457 W EP2005007457 W EP 2005007457W WO 2006008008 A3 WO2006008008 A3 WO 2006008008A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disorders
- diseases
- hnf4a
- therapeutics
- diagnostics
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04017447 | 2004-07-23 | ||
EP04017447.6 | 2004-07-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006008008A2 WO2006008008A2 (fr) | 2006-01-26 |
WO2006008008A3 true WO2006008008A3 (fr) | 2006-06-22 |
Family
ID=35618139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/007457 WO2006008008A2 (fr) | 2004-07-23 | 2005-07-09 | Agents diagnostiques et therapeutiques pour pathologies associees au facteur nucleaire d'hepatocyte 4, alpha (hnf4a) |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2006008008A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9981048B2 (en) | 2013-02-12 | 2018-05-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods for the treatment and prevention of liver disease |
WO2023214405A1 (fr) * | 2022-05-01 | 2023-11-09 | Yeda Research And Development Co. Ltd. | Réexpression de hnf4a pour atténuer la cachexie associée au cancer |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998023780A1 (fr) * | 1996-11-26 | 1998-06-04 | Joslin Diabetes Center, Inc. | Procedes de diagnostic et de traitement du diabete |
US6025196A (en) * | 1990-12-21 | 2000-02-15 | The Rockefeller University | Chimeric proteins comprising liver enriched transcription factors and nucleic acids encoding the same |
WO2002024227A1 (fr) * | 2000-09-20 | 2002-03-28 | Kyowa Hakko Kogyo Co., Ltd. | Inhibiteurs de proliferation de cellules tumorales |
WO2002072874A1 (fr) * | 2001-03-14 | 2002-09-19 | Fujisawa Pharmaceutical Co., Ltd. | Procede de criblage d'un agoniste hnf4$g(a) |
WO2003016559A2 (fr) * | 2001-08-17 | 2003-02-27 | Novo Nordisk A/S | Procede de traitement du diabete |
WO2003064628A2 (fr) * | 2002-02-01 | 2003-08-07 | Curagen Corporation | Mandrin a vide faisant intervenir un materiau fritte et procede de fabrication |
WO2004023973A2 (fr) * | 2002-09-12 | 2004-03-25 | Incyte Corporation | Molecules utilisees a des fins diagnostiques et therapeutiques |
-
2005
- 2005-07-09 WO PCT/EP2005/007457 patent/WO2006008008A2/fr active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6025196A (en) * | 1990-12-21 | 2000-02-15 | The Rockefeller University | Chimeric proteins comprising liver enriched transcription factors and nucleic acids encoding the same |
WO1998023780A1 (fr) * | 1996-11-26 | 1998-06-04 | Joslin Diabetes Center, Inc. | Procedes de diagnostic et de traitement du diabete |
WO2002024227A1 (fr) * | 2000-09-20 | 2002-03-28 | Kyowa Hakko Kogyo Co., Ltd. | Inhibiteurs de proliferation de cellules tumorales |
WO2002072874A1 (fr) * | 2001-03-14 | 2002-09-19 | Fujisawa Pharmaceutical Co., Ltd. | Procede de criblage d'un agoniste hnf4$g(a) |
WO2003016559A2 (fr) * | 2001-08-17 | 2003-02-27 | Novo Nordisk A/S | Procede de traitement du diabete |
WO2003064628A2 (fr) * | 2002-02-01 | 2003-08-07 | Curagen Corporation | Mandrin a vide faisant intervenir un materiau fritte et procede de fabrication |
WO2004023973A2 (fr) * | 2002-09-12 | 2004-03-25 | Incyte Corporation | Molecules utilisees a des fins diagnostiques et therapeutiques |
Also Published As
Publication number | Publication date |
---|---|
WO2006008008A2 (fr) | 2006-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005106492A3 (fr) | Diagnostic et traitement therapeutique des maladies associees au recepteur 3 de la chimiokine c-c (ccr3) | |
WO2005075665A3 (fr) | Agents diagnostiques et therapeutiques pour des maladies associees a la kallikreine plasmatique (klkb1) | |
WO2006008002A3 (fr) | Agents diagnostiques et therapeutiques pour pathologies associees a la kallikreine 1 (klk1) | |
WO2004104216A3 (fr) | Diagnostics et agents therapeutiques destines a des maladies liees a une dipeptidylpeptidase iv (dpp4) | |
WO2004104215A3 (fr) | Approches diagnostiques et therapeutiques des maladies associees a la dipeptidylpeptidase 7 (dpp7) | |
WO2005095973A3 (fr) | Methodes diagnostiques et therapeutiques pour des maladies associees au recepteur 54 couple a la proteine g (gpr54) | |
WO2005103702A3 (fr) | Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees au recepteur 2 de la chimiokine cxc (cxcr2) | |
WO2005106471A3 (fr) | Diagnostics et therapies pour des maladies associees a un recepteur 4 de chimiokine c-c (ccr4) | |
WO2005078117A3 (fr) | Agents diagnostiques et therapeutiques destines a des maladies associees a la kallikreine 6 (klk6) | |
WO2005118840A3 (fr) | Elements diagnostiques therapeutiques pour des maladies associees a la kallikreine 10 (klk10) | |
WO2006008008A3 (fr) | Agents diagnostiques et therapeutiques pour pathologies associees au facteur nucleaire d'hepatocyte 4, alpha (hnf4a) | |
WO2005075662A3 (fr) | Methodes diagnostiques et therapeutiques des maladies associees au kallikrein 2 (klk2) | |
WO2005050225A3 (fr) | Outils de diagnostic et de traitement de maladies associees au recepteur 84 couple aux proteines g (gpr84) | |
WO2004082568A3 (fr) | Diagnostics et traitements contre des maladies associees au recepteur 5a du composant du complement (c5ar) | |
WO2005083105A3 (fr) | Diagnostic et traitement de maladies associees a la glycogene synthase kinase 3 beta (gsk3b) | |
WO2005106488A3 (fr) | Diagnostics et therapeutique de maladies associees a l'adrenorecepteur beta-2 couple aux proteines g (adrb2) | |
WO2005095984A3 (fr) | Compositions diagnostiques et therapeutiques pour des maladies associees au recepteur adrenergique alpha 2a couple a la proteine g (adra2a) | |
WO2005103711A3 (fr) | Agents diagnostiques et therapeutiques pour des maladies associees au recepteur 1 des chimiokines cxc (cxcr1) | |
WO2004104574A3 (fr) | Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur de chimiokine c-c de type 7 (ccr7) | |
WO2005103690A3 (fr) | Diagnostic et therapeutique de maladies associees au recepteur de l'hormone de liberation de la corticotropine 2 (crhr2) | |
WO2005040211A3 (fr) | Composes destines au diagnostic et au traitement de maladies associees au recepteur 1 couple aux proteines g (gpr1) | |
WO2005108998A3 (fr) | Methodes de diagnostic et de traitement de maladies associees au recepteur couple aux proteines g adrenergique beta-3 (adrb3) | |
WO2005059546A3 (fr) | Diagnostics et therapeutique destines au traitement de maladies associees au recepteur couple aux proteines g 35 (gpr35) | |
WO2005040825A3 (fr) | Diagnostics et therapeutiques pour maladies liees au recepteur 20 couple a la proteine g (gpr20) | |
WO2004106934A3 (fr) | Diagnostics et agents therapeutiques destines a des maladies liees au recepteur 7 de 5-hydroxytryptamine (serotonine) (5-ht7) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |